CeriBell (NASDAQ:CBLL) reported third-quarter revenue growth of approximately 30% as the company added a record number of hospital accounts and increased usage of its seizure-monitoring platform among existing customers. Management also outlined plans to commercially launch its Delirium Monitoring Solution and introduce its next-generation Omni hardware platform in 2027.
Revenue for the quarter ended Sept. 30 totaled $29.3 million, up from $22.6 million a year earlier and 4% higher sequentially. Product revenue rose 31% to $22.2 million, while subscription revenue increased 28% to $7.1 million.
“Underlying growth was driven by success across both core revenue drivers, adoption by more accounts and deeper penetration within our install base,” Co-founder and Chief Executive Officer Jane Chao said on the company’s earnings call.
Record Account Additions and Higher Utilization
CeriBell ended the third quarter with 747 active hospital accounts after adding 35 hospitals during the period, its largest quarterly account increase to date. Chao said the company continues to maintain a pipeline of unlaunched accounts that it expects to support growth in coming quarters.
Headband utilization per account grew at a double-digit year-over-year rate, which management described as the highest since the company’s initial public offering. The company attributed the increase to provider engagement, expansion into additional hospital departments and protocolization across patient populations.
Department expansion has accelerated in 2026, according to Chao, with the company expanding into more departments year to date than it did during all of 2025. CeriBell has been focused on expanding its presence in intensive-care units and emergency departments.
During the question-and-answer session, Chief Financial Officer Scott Blumberg said the company monitors utilization closely because its cloud-enabled platform provides data on when its systems are being used and on usage patterns. He said utilization is the company’s core long-term operating metric, even though purchases can vary from quarter to quarter.
Management also cited progress with strategic health-system accounts and government customers. CeriBell secured a commitment to expand within the Department of Veterans Affairs system, with the related account additions expected to enter its active base over the next two to three quarters. Blumberg said the size of the VA commitment was “reasonably in line” with the prior year.
Delirium Monitoring Moves Into Commercial Launch
The company recently launched its Delirium Monitoring Solution following a commercial pilot with customers already using its seizure platform. Chao said the pilot showed clinical utility and resulted in a material increase in headband utilization among participating accounts.
CeriBell’s system is intended to support simultaneous monitoring for seizure and delirium, and management said it can be difficult to separate the usage contribution from each condition. Chao said the company observed expansion into additional patient populations, including patients with sepsis, as well as increased engagement with nursing and physician teams.
The company is offering the delirium solution as a software upgrade at no incremental subscription fee for existing customers. Instead, CeriBell is asking participating hospitals to make program commitments, including training more than 80% of nurses and physicians during the launch process, aligning on delirium-monitoring and management key performance indicators, and ensuring sufficient recorder capacity.
Management said this model is designed to avoid lengthy contracting processes while supporting more effective implementation. However, Chao said broad conversion of the existing customer base will occur over time rather than immediately.
CeriBell did not quantify the pilot’s utilization increase or provide a timetable for rolling the delirium solution across all accounts. The company said it expects to offer a more detailed view of the product’s expected revenue contribution when it provides 2027 financial guidance. Management said neonatal, pediatric and delirium products are not expected to contribute materially to 2026 revenue, with more meaningful contributions anticipated in 2027.
Omni Platform and Algorithm Development
CeriBell also disclosed the name of its next-generation hardware platform, Omni, which is scheduled for a limited market release during the fourth quarter and a broader launch in 2027.
The Omni platform is designed to combine point-of-care EEG capabilities with features associated with conventional EEG. Management said the platform will include video, multiple-day continuous monitoring, EKG compatibility and a parasagittal add-on for full montage coverage. It is also designed to operate the company’s FDA-cleared algorithms for seizure, status epilepticus, delirium and other indicators of brain stress.
The company recently received FDA 510(k) clearances for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis algorithms. These software features, which include alpha-delta ratio, relative alpha trending and burst suppression monitoring, are expected to be released through a cloud-based update next year. CeriBell said its large-vessel-occlusion stroke clinical program is also continuing.
Margins Remain High, While Loss Widens
Third-quarter gross margin was 90%, compared with 88% in the prior-year period. Blumberg said the company expects gross margins to remain in the high-80% range based on current tariff policy and inventory levels.
Operating expenses increased 36% to $46.9 million as CeriBell continued to invest in its commercial infrastructure, research and development, and strategic account-management capabilities. Sales and marketing expense was $25 million, while research and development expense was $7.4 million. General and administrative expense included $1.1 million related to ongoing intellectual-property litigation.
Net loss widened to $21.4 million, or $0.55 per share, from $13.5 million, or $0.37 per share, a year earlier. Adjusted EBITDA loss was $12.1 million, compared with a $9.2 million loss in the prior-year quarter.
CeriBell held $117.5 million in cash equivalents and marketable securities as of Sept. 30. Blumberg said the company remains committed to reaching cash-flow breakeven with cash on hand. He added that the company has largely made the infrastructure investments needed to support the initiatives currently in front of it, while continuing to evaluate spending decisions quarter by quarter.
For full-year 2026, CeriBell raised the lower end of its revenue outlook and now expects revenue of $115 million to $117 million, compared with prior guidance of $114 million to $117 million. The revised range represents growth of 29% to 31% over 2025.
About CeriBell (NASDAQ:CBLL)
CeriBell, Inc is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.
The company’s primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools.
